chrisvoncsefalvay/vaers-outcomes huggingface dataset:
inappropriate schedule of vaccine administered; Swollen lymph nodes in armpit on both sides, worse on left.; Swollen arm at injection site; Red arm at injection site; This is a spontaneous report from a contactable consumer, the patient. A 64-year-old non-pregnant female patient received the second dose of BNT162b2 (PFIZER-BIONTECH COVID-19 mRNA VACCINE; Lot Number: UNKNOWN) via an unspecified route of administration in the arm left on 29Mar2021 at 10:15 (at the age of 64-year-old) as a single dose for COVID-19 immunisation. The patient medical history was not reported. Concomitant medications included fluoxetine hydrochloride (PROZAC), bupropion hydrochloride (WELLBUTRIN), Vit D (MANUFACTURER UNKNOWN), folic acid (MANUFACTURER UNKNOWN), magnesium (MANUFACTURER UNKNOWN) and calcium (MANUFACTURER UNKNOWN) for an unknown indication from an unknown date. The patient previously received the first dose of BNT162b2 (PFIZER-BIONTECH COVID-19 mRNA vaccine; Lot number: unknown) via an unspecified route of administration in the left arm on 15Mar2021 (at the age of 64-years-old) as a single dose for COVID-19 immunisation. The patient had known allergies to penicillin. The patient did not receive any medications within two weeks of vaccination. The patient did not receive any other vaccines within 4 weeks prior to the COVID vaccine. Prior to vaccination, the patient was not diagnosed with COVID-19. Since the vaccination, the patient was not tested for COVID-19. On 31Mar2021 at 18:00, the patient experienced swollen lymph nodes in armpit on both the sides, worse on the left, swollen and red arm at injection site. The vaccine was administered outside the range of 19-42 days after the first dose. The events did not result in a visit to the doctors or other healthcare professional office/clinic visit, and emergency room/department or urgent care. No therapeutic measures were taken as a result of the reported events. The clinical outcome of the events swollen lymph nodes in armpit on both the sides, worse on the left, swollen and red arm at injection site were not recovered at the time of report.   No follow-up attempts are needed; information about lot/batch number cannot be obtained.
This medically confirmed spontaneous report (initial receipt 28-OCT-2014) concerns a 55 year old male patient. On 26-OCT-2014, AFLURIA underwent temperature excursion at 50 degree Fahrenheit. On 27-OCT-2014, AFLURIA again had temperature excursion at 50 degree Fahrenheit for undetermined amount of time. On 27-OCT-2014, the patient received temperature excursion AFLURIA (batch number: T50507) via intramuscular route at 0.5 ml. Outcome was reported as unknown. Reporter's comments: The reporter assessed the event as non-serious.
bumps on the deltoid and they were experiencing side effects, such as chills; bumps on the deltoid and they were experiencing side effects, such as chills; This is a spontaneous report received from a contactable reporter(s) (Consumer or other non HCP) from medical information team.  A patient (no qualifiers provided) received bnt162b2 (BNT162B2) (Batch/Lot number: unknown) as dose number unknown, single for covid-19 immunisation. The patient's relevant medical history and concomitant medications were not reported. The following information was reported: CHILLS (non-serious), VACCINATION SITE INDURATION (non-serious), outcome "unknown" and all described as "bumps on the deltoid and they were experiencing side effects, such as chills". No follow-up attempts are possible; information about lot/batch number cannot be obtained. No further information is expected.
I started getting symptoms of fatigue and tiredness. The next morning, I was nauseas and was vomiting. I had extreme body aches. My daughter took me to get tested. I received a positive COVID-19 test. I called my doctor which prescribed me an antibiotic. I lost taste and smell and on the fourth day, my taste and smell came back. I had pain and heaviness in my chest. My symptoms lasted over one week. After 7 days, I had another COVID test which was still positive.
Seizures around 7 pm the same day; Cough; Severe congestion; Freezing cold all the time; Muscle spasms; Heart palpitations; Numbness of my hands and feet; Severe tremors in my hands; Dizziness; Weight loss; Menstrual cramps; Has affected my menstrual cycle severely; Loss of appetite; Headaches; Had extreme fatigue; This is a spontaneous report from a contactable consumer (patient). A 31-years-old female non-pregnant patient received bnt162b2 (PFIZER-BIONTECH COVID-19 mRNA VACCINE; Solution for injection, Lot Number: EW0175), via an unspecified route of administration in the left arm on 10Jun2021 at 11:40 as a dose 2, single for COVID-19 immunization (at the age of 31-years-old). Medical history included Known allergies: Soy from an unknown date and unknown if ongoing.There were no concomitant medications. Historical vaccine included first dose of bnt162b2 (PFIZER-BIONTECH COVID-19 mRNA VACCINE; Solution for injection, Lot Number: EW0173), via an unspecified route of administration in the left arm on 20May2021 at 12:00 as a dose 1, single for COVID-19 immunization (at the age of 31-years-old). The patient did not receive any medication within 2 weeks of vaccination. The patient did not receive any other vaccines within 4 weeks prior to the COVID-19 vaccine. Prior to vaccination, the patient was not diagnosed with COVID-19. Since the vaccination, the patient had not been tested for COVID-19. The patient stated that she had two seizures around 7 pm the same day (10Jun2021 19:00). Since her second dose of Pfizer, 10Jun2021 13:00, she have had extreme fatigue, cough, severe congestion, freezing cold all the time, muscle spasms, heart palpitations, numbness of my hands and feet, severe tremors in my hands, headaches, dizziness, loss of appetite, weight loss, menstrual cramps every day and has affected her menstrual cycle severely. The patient did not receive any treatment. The clinical outcome for the events was not recovered.  Follow-up attempts are completed. No further information is expected
Soreness at injection site: 48 hour duration Headache: 24 hour duration Body Aches: 24 hour duration Slight Temperature Increase (99.6 F): 24 hour duration Fatigue: 24 hour duration
This spontaneous report as received from a medical assistant refers to a 2 month old female patient without known drug allergies and reactions. On 25-NOV-2014 the patient was vaccinated with ROTATEQ dose 1, 1 ml, oral, lot # reported as K009745, expiration date reported as 17-FEB-2016. On 25-NOV-2014, immediately after receiving the dose of ROTATEQ, she started to foam at the mouth and have difficulty breathing. The patient also had nostril flaring and experienced shortness of breath. The unspecified Emergency Services were called to the physician's office. The Medical assistant considered this to be both life threatening and a significant incapacity to the patient. The patient was given an unspecified nebulizer treatment while in the physician's office and then taken by ambulance to an unspecified hospital. It was unspecified as to if the patient was admitted to a hospital. The outcome of the events was unknown. Additional information has been requested.
Given varicella (L) arm on 12/21/10 came in 12/22/10 with redness & swelling at inj. site length 3 cm width 2 cm.
Dose given 12 hours after the puncture; This spontaneous case was reported by a pharmacist and describes the occurrence of EXPIRED PRODUCT ADMINISTERED (Dose given 12 hours after the puncture) in a female patient of an unknown age who received mRNA-1273 (Moderna COVID-19 Vaccine) for COVID-19 vaccination.     The patient's past medical history included Multiple fractures (Multi Fx) and Dementia. Concurrent medical conditions included Type 2 diabetes mellitus (DMT2) and Acute kidney failure (AKF). Concomitant products included CLONIDINE, FENTANYL, HYDRALAZINE, HYOSCYAMINE SULFATE (LEVSIN) and SENNOSIDE A+B (SENNA [SENNOSIDE A+B]) for an unknown indication.   On 24-Jan-2021, the patient received first dose of mRNA-1273 (Moderna COVID-19 Vaccine) (unknown route) 1 dosage form. On 23-Feb-2021, received second dose of mRNA-1273 (Moderna COVID-19 Vaccine) (unknown route) dosage was changed to 1 dosage form. On 19-Nov-2021, received third dose of mRNA-1273 (Moderna COVID-19 Vaccine) (unknown route) dosage was changed to 1 dosage form. On 19-Nov-2021,  after starting mRNA-1273 (Moderna COVID-19 Vaccine), the patient experienced EXPIRED PRODUCT ADMINISTERED (Dose given 12 hours after the puncture). On 19-Nov-2021, EXPIRED PRODUCT ADMINISTERED (Dose given 12 hours after the puncture) had resolved.        For mRNA-1273 (Moderna COVID-19 Vaccine) (Unknown), the reporter did not provide any causality assessments.   No treatment medications reported. No adverse outcomes noted.  It was reported that dose was given greater than 12 hours after the vial was punctured.   This case was linked to MOD-2021-416295 (Patient Link).
This is a spontaneous report received from a contactable reporter(s) (Consumer or other non HCP). The reporter is the patient.  A 63-year-old female patient (not pregnant) received BNT162b2 (BNT162B2), on 10May2022 at 14:30 as dose 4 (booster), single (Lot number: FK9893) at the age of 63 years, in left arm for covid-19 immunization. The patient's relevant medical history included: "Hasimoto disease" (unspecified if ongoing); "Allergy" (unspecified if ongoing). Concomitant medication(s) included: LEVOTHYROXINE; VITAMIN D [VITAMIN D NOS]; BABY ASPIRIN; B COMPLEX [VITAMIN B COMPLEX]. Vaccination history included: Covid-19 vaccine (DOSE 1; MANUFACTURER UNKNOWN), for COVID-19 immunization; Covid-19 vaccine (DOSE 2; MANUFACTURER UNKNOWN), for COVID-19 immunization; Covid-19 vaccine (DOSE 3 (BOOSTER); MANUFACTURER UNKNOWN), for COVID-19 immunization. The following information was reported: CHILLS (non-serious) with onset 11May2022 at 02:00, outcome "recovering"; PAIN (non-serious) with onset 11May2022 at 02:00, outcome "recovering", described as "body aches"; BURNING SENSATION (non-serious) with onset 11May2022 at 02:00, outcome "recovering", described as "burning fingertips"; SINUS DISORDER (non-serious) with onset 11May2022 at 02:00, outcome "recovering", described as "dried out sinuses"; FATIGUE (non-serious) with onset 11May2022 at 02:00, outcome "recovering"; HEADACHE (non-serious) with onset 11May2022 at 02:00, outcome "recovering", described as "headaches"; ARTHRALGIA (non-serious) with onset 11May2022 at 02:00, outcome "recovering", described as "joint aches". Therapeutic measures were not taken as a result of chills, burning sensation, pain, headache, arthralgia, sinus disorder, fatigue.  Additional information: The patient did not receive any other vaccines within four weeks prior to the COVID-19 vaccine. Prior to vaccination, the patient was not diagnosed with COVID-19. Since the vaccination, the patient had not been tested for COVID-19.  No follow-up attempts are possible. No further information is expected.
Dizziness, pain, general feeling of illness. Went to hospital after MD visit. Had Xrays & CBC. Various tests in hospital.
Soreness in the injection site and swollen lymph nodes.  Patient has called several times to update department that soreness still exists and that lymph nodes are still swollen.  Last call 12/14/11.  We reported this to our State Immunization program as well as updated our county health officer.  Patient did travel out of the county after receiving the vaccination.  We followed up with the patient by phone calls.
I tested positive for COVID-19 on 03/16/2023. I had tested negative twice and went into the clinic, I had a fever of 100.2 degrees. I took a flu test and chest X-Ray, two days later my wife became sick the same way I was and she tested positive so I tested again and was positive. I had stuffiness, congestion, high fever and a cough. I was prescribed Paxlovid, I started it on March 17th, 2023.
On 10/18/2021 client returned for vaccine number two of Moderna.  It was discovered at that time, that she should have not received Moderna, Pfizer was age appropriate.  Mother and Father were informed.  Mother was asked if client had adverse reaction she said, yes.  Was asked if it was fever,chills and aches and she said,yes.  Mother was informed that was a normal immune response to a vaccine.  Parents were informed that the CDC was called and they suggested giving a 2nd Moderna vaccine and report the event to VAERS.  Parents were given a written copy CDC's suggestion along with CDC's number and information on how to contact VAERS.
Bells Palsy left side of face. Dx with strep 8/25/03. Tx with PCN.
Information has been received from a physician and the office manager concerning a 6 month old male patient who on 10-MAR-2009, was vaccinated with PNEUMOVAX (lot # 661934/1441X) instead of PREVNAR by mistake due to an office error. It is unknown if the patient sought medical attention. Follow up information was received from the physician which reported that the patient was vaccinated IM with PNEUMOVAX (lot # 661934/1441X). There was no illness at the time of vaccination. No reactions or adverse events were reported. The patient did not seek medical attention. This is one of several reports from the same source. Additional information is not expected.
Employee received .2 cc of Pfizer instead of .3 cc which was inadvertently administrated by vaccine nurse.   NO ADVERSE REACTION, just reporting medication error.   Our Vaccine Task Force, after speaking with CDC and department of health, decided to offer the employee an additional COVID-19 vaccine dose. Thanks.
very bad, do not have specifics pt spoke to her MD, they said do not get 2nd dose
Treatment of COVID-19; Treatment of COVID-19; This is a spontaneous report received from a contactable reporter(s) (Consumer or other non HCP). The reporter is the patient.  A 57-year-old male patient received BNT162b2 (BNT162B2), on 15Apr2022 as dose 4 (booster), single (Batch/Lot number: unknown) at the age of 57 years, in left arm for covid-19 immunisation; coviD-19 vaccine (COVID-19 VACCINE), as dose 1, single (Batch/Lot number: unknown), as dose 2, single (Batch/Lot number: unknown) and as dose 3 (booster), single (Batch/Lot number: unknown) for covid-19 immunisation. The patient's relevant medical history included: "Hypertension" (unspecified if ongoing). Concomitant medication(s) included: HYDROCHLOROTHIAZIDE, start date: Jul2009; LOSARTAN, start date: Jul2009. The following information was reported: DRUG INEFFECTIVE (medically significant), COVID-19 (medically significant) all with onset Sep2022, outcome "unknown" and all described as "Treatment of COVID-19". Therapeutic measures were taken as a result of drug ineffective, covid-19 included Paxlovid received from 15Sep2022-19Sep2022.  The information on the batch/lot number for BNT162b2 has been requested and will be submitted if and when received.
Pt vaccinated with DTP/OPV unconsolable screaming/crying for 3 hrs, then another 5-6 hrs irritability.
pt recv vax 28JUN95 temp started that afternoon up to 101.8; febrile 28JUN, 29JUN 30JUN & 1/2 day 1JUL; rash appeared 2JUL95-probable roseola
Pain at the time of injection; Induration of 1.5 cm in size approximately 4 or 5 cm lower than actual injection site; Area below the injection site is red; Area below the injection site is tender; This case was reported by a nurse via call center representative and described the occurrence of injection site pain in a 65-year-old male patient who received Herpes zoster (Shingrix) (batch number HY4GT, expiry date 21st September 2021) for prophylaxis.   On 2nd November 2019, the patient received the 2nd dose of Shingrix. In November 2019, less than a week after receiving Shingrix, the patient experienced injection site pain, injection site induration, injection site erythema and injection site tenderness. On an unknown date, the outcome of the injection site pain, injection site induration, injection site erythema and injection site tenderness were unknown.   It was unknown if the reporter considered the injection site pain, injection site induration, injection site erythema and injection site tenderness to be related to Shingrix.  Additional details were provided as follows: This case was reported by the family nurse practitioner for her husband. The patient experienced pain at the time of injection, and is experiencing induration of 1.5 cm in size approximately 4 or 5 cm lower than actual injection site. The area was tender and red.  The reporter consented to follow up. This case is 1 of the 3 linked cases, reported by the same reporter.
pt recv vax approx 11AM 9FEB98 & mom returned 10PM & stated pt vomited x 4 since 1PM;MD ordered DPH;
Patients arm became swollen several hours after vaccine admin of PNEUMOVAX.  Warm to the touch the next day.  Pt took ibuprofen and BENADRYL on 10/2/08.  Went to MD on 10/3/08 and MD diagnosed as cellulitis and treated w/ CEFTIN.
shingles onset after vaccine second dose; highly unusual and painful; difficulty breathing; nerve pain; nerve eruptions bilateral sacral dorsal area; bilateral sores in sacral dorsal area; weeping painful sores; This spontaneous case was reported by a consumer and describes the occurrence of HERPES ZOSTER (shingles onset after vaccine second dose), PAIN (highly unusual and painful), DYSPNOEA (difficulty breathing), NEURALGIA (nerve pain) and RASH (nerve eruptions bilateral sacral dorsal area) in a 62-year-old female patient who received mRNA-1273 (Moderna COVID-19 Vaccine) (batch no. 044B21A) for COVID-19 vaccination. The occurrence of additional non-serious events is detailed below.     No Medical History information was reported.    On 19-Apr-2021, the patient received second dose of mRNA-1273 (Moderna COVID-19 Vaccine) (Intramuscular) 1 dosage form. On 19-Apr-2021, the patient experienced HERPES ZOSTER (shingles onset after vaccine second dose), PAIN (highly unusual and painful), DYSPNOEA (difficulty breathing), NEURALGIA (nerve pain), RASH (nerve eruptions bilateral sacral dorsal area), BLISTER (bilateral sores in sacral dorsal area) and ABSCESS (weeping painful sores). At the time of the report, HERPES ZOSTER (shingles onset after vaccine second dose), PAIN (highly unusual and painful), DYSPNOEA (difficulty breathing), NEURALGIA (nerve pain), RASH (nerve eruptions bilateral sacral dorsal area), BLISTER (bilateral sores in sacral dorsal area) and ABSCESS (weeping painful sores) outcome was unknown.            No concomitant medications were provided. Treatment medication reported includes Medical Cannabis to help sleep through pain and Naproxen 220 mg.
This is a spontaneous report from a contactable physician. A 40-year-old female (non-pregnant) patient received a single dose of TRUMENBA on 17Jul2015. Relevant medical history included menstrual-associated migraines. Concomitant medications were unknown. The patient previously took meningococcal quadrivalent conjugate vaccine (MCV 4). She was in her usual state of good health until on 17Jul2015 (Friday) when she received TRUMENBA since she was recommended to receive it because of her occupational exposure (she was a microbiology technician). On an unspecified date, the patient experienced a very large local reaction. Within 2 hours of vaccine receipt, on 17Jul2015, the patient complained of arm pain. Then later in the evening, she experienced chills and her upper arm became more painful, warm, and erythematous in the area surrounding where the vaccine was administered. On the next day, 18Jul2015, she noted an enlarged, raised, erythematous area at the injection site. She also had generalized body aches, and mild, subjective fever, but no GI or URI symptoms. Then on the next day, 19Jul2015, she developed a severe headache, different from her usual migraine headaches. The patient spent the weekend on the couch, feeling as if she had a 'bad flu' with sore, hot arm, body aches, malaise/fatigue, and headache. She never went to ER and was not hospitalized. Over the next 5-7 day period, her arm improved and as the redness and swelling subsided, the involved skin on the upper arm felt 'coarse', like sandpaper. In the area surrounding the injection there were no pustules, no discrete lesions, and no vesicles. There was no pruritus initially, but some developed over time. She did not take acetaminophen or any NSAIDs. The outcome of the events arm pain and vaccination site erythema was recovering. The outcome of all other events was not reported. Follow up (19Oct2015): New information received from a contactable physician includes: patient's age; administration date; medical history; clinical course; 'arm pain', 'chills', 'her upper arm became more painful, warm, and erythematous in the area surrounding where the vaccine was administered', 'enlarged, raised, erythematous area at the injection site', 'generalized body aches/body aches', 'mild subjective fever', 'severe headache, different from her usual migraine headaches/headache', 'malaise', 'fatigue', 'feeling as if she had a bad flu with sore' and 'pruritus' added as events.
DTP #2 given 10JAN92 & on 11JAN92 & 12JAN92 had irritability w/high pitched cry; no change in eating, sleeping, napping; pt has colic but cry & behavior is different; some jerking movements;
12/09/2021: admitted with complaints of SOB and difficulty breathing with a cough productive of bright red blood. Positive for COVID 10 days ago. Patient had a hx of PE in 2019.  12/09/2021 - 12/10/2021: treated with Decadron x 1, Vibramycin, Rocephin, supp oxygen, Xarelto holding  12/10/2021: stable without oxygen support, improved sx since admission. Hemoptysis resolved. Discharged
Began getting fever, headache, runny nose around 8/20/21 after returning from 10 day trip.  Talked with primary care doctor and was advised to get a COVID test done (since I  just travelled out of state).  Tested on 8/25/21.
Complained of sore throat, fever 101, cough, headache, runny nose and flu like symptoms, began approx 4-6 hours after vaccination. Follow up 08/25/2005 improved and no fever resolving symptoms.
Had some normal and expected vaccine symptoms... But my heart has been racing, even at the slightest exercise. I also have sharp chest pain when I breathe deeply or sometimes during mild breathing.
Around 11 pm started coughing and wheezing it stopped after I inhaled Flovent. The next event happened around 1:30 am I woke up with shivers, heart racing, and vomiting. This event lasted until 2 am.  When I woke up at 7 am my stomach felt very weak and my arms and body were very achy.
Starting the evening of vaccination dose #2, experienced severe joint pain all over, red/swollen knees, feet, and hands as well as altered mental status. Mental status improved on post-vaccine day 4. Joint pain and swelling persisted. Presented to rheumatologist 2/1/2021 for evaluation as symptoms were not improving. "She has some synovitis on exam and endorses increased joint pain, swelling, and morning stiffness. At this time will treat with a steroid taper to see if symptoms can get under control. If symptoms persist will need to consider restarting DMARD therapy. Prednisone 15 mg daily for 7 days, then 10 mg daily for 14 days, then 5 mg daily for 14 days. Then off. " Did not tolerate adverse effects of prednisone and taper changed on 2/10/2021 to 10 mg for 5 days and then 5 mg for 5 days and then off.  Joint pain continues.
10 days post 2nd shot (Sept 13), developed severe nausea, swollen lymph nodes in neck, tinnutus, and left ear pressure. Went to general practitioner 1 week after symptoms did not improve. Was prescribed Zofran and Phenergan with little effect. Next prescribed a steroid shot and antibiotics for possible ear infection. Next was referred to ENT Dr who prescribed steroid pack and another antibiotic. Symptoms persist at 9 weeks post-vaccination.